We are live on ! Find out more
GFM

GF Fund Management Portfolio holdings

AUM $8.34B
1-Year Est. Return 165.53%
This Fund
S&P 500
This Quarter Est. Return
+77.9%
1 Year Est. Return
+165.53%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$8.34B
AUM Growth
+$2.35B
Cap. Flow
-$42M
Cap. Flow %
-0.5%
Top 10 Hldgs %
46.57%
Holding
644
New
20
Increased
132
Reduced
424
Closed
57

Top Sells

Rank Stock Value
1
TSEM icon
Tower Semiconductor
TSEM
+$220M
2
LITE icon
Lumentum
LITE
+$219M
3
TSLA icon
Tesla
TSLA
+$50.1M
4
CIEN icon
Ciena
CIEN
+$43.3M
5
MSFT icon
Microsoft
MSFT
+$42.6M

Sector Composition

Rank Sector Weight
1 Technology 66.11%
2 Communication Services 9.64%
3 Consumer Discretionary 8.42%
4 Industrials 4.35%
5 Healthcare 4.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PTCT icon
301
PTC Therapeutics
PTCT
$5.78B
$143K ﹤0.01%
1,753
-50
-3% -$3.61K
AMH icon
302
American Homes 4 Rent
AMH
$11.7B
$142K ﹤0.01%
4,238
-799
-16% -$25.3K
AHR icon
303
American Healthcare REIT
AHR
$11.9B
$135K ﹤0.01%
2,597
+48
+2% +$2.36K
LGND icon
304
Ligand Pharmaceuticals
LGND
$5.69B
$134K ﹤0.01%
425
-18
-4% -$4.24K
TWST icon
305
Twist Bioscience
TWST
$8.21B
$134K ﹤0.01%
1,300
-73
-5% -$4.75K
BXP icon
306
Boston Properties
BXP
$10.8B
$134K ﹤0.01%
2,015
-260
-11% -$15.6K
COGT icon
307
Cogent Biosciences
COGT
$6.03B
$133K ﹤0.01%
3,435
-12
-0.3% -$420
FRT icon
308
Federal Realty Investment Trust
FRT
$10.2B
$127K ﹤0.01%
1,031
-209
-17% -$24.3K
CGON icon
309
CG Oncology
CGON
$6.62B
$127K ﹤0.01%
1,789
-23
-1% -$1.5K
ADC icon
310
Agree Realty
ADC
$9.03B
$122K ﹤0.01%
1,617
-56
-3% -$4.24K
BRX icon
311
Brixmor Property Group
BRX
$8.95B
$122K ﹤0.01%
3,878
-749
-16% -$22.9K
CUBE icon
312
CubeSmart
CUBE
$8.89B
$121K ﹤0.01%
3,038
-409
-12% -$16.3K
CTRE icon
313
CareTrust REIT
CTRE
$9.22B
$121K ﹤0.01%
2,994
-381
-11% -$15K
EGY icon
314
Vaalco Energy
EGY
$631M
$121K ﹤0.01%
23,723
-11,907
-33% -$68.6K
ERAS icon
315
Erasca
ERAS
$5.66B
$120K ﹤0.01%
6,552
+180
+3% +$2.57K
NNN icon
316
NNN REIT
NNN
$8.57B
$120K ﹤0.01%
2,570
-284
-10% -$12.7K
SRRK icon
317
Scholar Rock
SRRK
$6.74B
$119K ﹤0.01%
2,161
-130
-6% -$6.28K
XOM icon
318
ExxonMobil
XOM
$656B
$118K ﹤0.01%
862
-1,106
-56% -$166K
ACN icon
319
Accenture
ACN
$114B
$118K ﹤0.01%
947
-485
-34% -$84.2K
AMRX icon
320
Amneal Pharmaceuticals
AMRX
$6.07B
$115K ﹤0.01%
6,656
-404
-6% -$5.54K
ORKA
321
Oruka Therapeutics
ORKA
$6.13B
$113K ﹤0.01%
1,192
+105
+10% +$7K
TVTX icon
322
Travere Therapeutics
TVTX
$6.15B
$111K ﹤0.01%
1,955
-54
-3% -$2.39K
CRSP icon
323
CRISPR Therapeutics
CRSP
$5.39B
$111K ﹤0.01%
2,032
-108
-5% -$5.69K
VTS icon
324
Vitesse Energy
VTS
$749M
$109K ﹤0.01%
6,929
-2,516
-27% -$44.5K
ARE icon
325
Alexandria Real Estate Equities
ARE
$9.06B
$109K ﹤0.01%
2,066
-287
-12% -$13.7K

Similar funds

GF Fund Management's Q2 2026 Portfolio in Review

As of Q2 2026, GF Fund Management held 644 positions worth $8.34B, up 39% from $5.98B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

GF Fund Management's Q2 2026 filing shows 20 new, 132 increased, 424 reduced and 57 closed positions. Its largest new stake was INNIO N.V.: 4,970,000 shares worth $197M. The largest sale was Tower Semiconductor, an estimated $220M.

By sector, the portfolio is most concentrated in Technology at 66% of assets, up from 54% a quarter earlier, followed by Communication Services and Consumer Discretionary.

  • GF Fund Management's largest Q2 2026 buy was INNIO N.V.: 4,970,000 shares worth $197M.
  • GF Fund Management added most to Advanced Micro Devices in Q2 2026, an estimated $119M increase.
  • GF Fund Management's biggest Q2 2026 reduction was Tower Semiconductor, cutting an estimated $220M.
  • GF Fund Management fully exited Coherent in Q2 2026, selling an estimated $23.3M.
  • GF Fund Management's ten largest holdings make up 47% of its $8.34B portfolio in Q2 2026.
  • GF Fund Management opened 20 new positions and closed 57 in Q2 2026.
  • GF Fund Management's portfolio value rose 39% quarter-over-quarter to $8.34B.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.